Clinically effective anti-PD-1 and anti-CTLA-4 antibodies, as well as TIM-3, a galectin-9 binding partner and a negative regulator of T cells, have been used as novel targets in tumor immunotherapy to enhance T cell antitumor function [82,83]. This evidence concerns the gene HAVCR2 and neoplasm.